The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Open accessAbstract
Background Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.Objective This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019.Methods We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019.Results Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus standard-of-care treatment (22 patients) or placebo based on standard-of-care treatment (21 patients). After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study. Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clinical improvement. Eighteen (90%) patients from the ruxolitinib group showed computed tomography improvement at day 14 compared with 13 (61.9%) patients from the control group (P = .0495). Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.Conclusions Although no statistical difference was observed, ruxolitinib recipients had a numerically faster clinical improvement. Significant chest computed tomography improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, ruxolitinib failed to show significant protection in the treatment of severe coronavirus disease (57) and the National Institutes of Health recommends against using ruxolitinib for the treatment of COVID-19 (https://bit.ly/3TtgsIe).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationPathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Self-citationA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258
Self-citationVEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Flagged first, then by citations
Research works printed but not linked: 1
- Yan, 2020, Evolution characteristics of thoracic lesions on CT of COVID-19 in recovery stage [in Chinese], Radiol Pract, 35, 428
Cited by
Sorted by citations
Items 101–200 of 464
Cancer therapy and treatments during COVID-19 era
Akula, S. M., Abrams, S. L., Steelman, L. S., Candido, S., Libra, M., Lerpiriyapong, K., Cocco, L., Ramazzotti, G., Ratti, S., Follo, M. Y., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100739 · Cited by 47
Alunno, A., Najm, A., Mariette, X., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219725 · Cited by 45
Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1759 · Cited by 47
Huarte, E., Peel, M. T., Verbist, K., Fay, B. L., Bassett, R., Albeituni, S., Nichols, K. E., & Smith, P. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650295 · Cited by 44
Han, Q., Guo, M., Zheng, Y., Zhang, Y., De, Y., Xu, C., Zhang, L., Sun, R., Lv, Y., Liang, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.615972 · Cited by 42
COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?
Jirjees, F., Saad, A. K., AlHano, Z., Hatahet, T., Al-Obaidi, H. J., & Bashi, Y. H. D. (2021) · Infectious Disease Reports · doi:10.3390/idr13020029 · Cited by 46
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
Maslennikov, R. V., Ivashkin, V. T., Vasilieva, E., Chipurik, M., Semikova, P., Semenets, V., Russkova, T., Levshina, A., Grigoriadis, D., Magomedov, S., et al. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102039 · Cited by 45
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Zhu, Y., Sharma, L., & Chang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1116131 · Cited by 57
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections
Raghuvanshi, R., & Bharate, S. B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01467 · Cited by 43
Feng, Z., Yang, J., Xu, M., Lin, R., Yang, H., Lai, L., Wang, Y., Wahner‐Roedler, D. L., Zhou, X., Shin, K.-M., et al. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.05.018 · Cited by 43
Self-citationSalomão, R., Assis, V., Neto, I. V. D. S., Petriz, B. A., Babault, N., Durigan, J. L. Q., & Marqueti, R. D. C. (2023) · Biology · doi:10.3390/biology12060843 · Cited by 44
Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines
Salahshoori, I., Mobaraki-Asl, N., Seyfaee, A., Nasirabad, N. M., Dehghan, Z., Faraji, M., Ganjkhani, M., Babapoor, A., Shadmehr, S., & Hamrang, A. (2021) · Biologics · doi:10.3390/biologics1010002 · Cited by 46
Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C. (2021) · Pharmaceuticals · doi:10.3390/ph14080738 · Cited by 45
Interleukin-6 blocking agents for treating COVID-19: a living systematic review
Ghosn, L., Assi, R., Evrenoglou, T., Buckley, B. S., Henschke, N., Probyn, K., Riveros, C., Davidson, M., Graña, C., Bonnet, H., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013881.pub2 · Cited by 45
Limen, R. Y., Sedono, R., Sugiarto, A., & Hariyanto, T. I. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1982695 · Cited by 41
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
Richardson, P. J., Robinson, B. W. S., Smith, D. P., & Stebbing, J. (2022) · Vaccines · doi:10.3390/vaccines10060951 · Cited by 44
Giesen, N., Sprute, R., Rüthrich, M. M., Khodamoradi, Y., Mellinghoff, S. C., Beutel, G., Lueck, C., Koldehoff, M., Hentrich, M., Sandherr, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.009 · Cited by 38
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
Chavda, V. P., Gajjar, N. D., Shah, N., & Dave, D. J. (2021) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2021.100013 · Cited by 39
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Ravid, J. D., Leiva, O., & Chitalia, V. C. (2022) · Cells · doi:10.3390/cells11020306 · Cited by 39
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Miao, Y., Fan, L., & Li, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01445 · Cited by 36
Current COVID-19 treatments: Rapid review of the literature
Dong, Y., Shamsuddin, A., Campbell, H. J., & Τheodoratou, E. (2021) · Journal of Global Health · doi:10.7189/jogh.11.10003 · Cited by 37
Chen, P., Tang, Y., He, W., Yang, R., Lan, Z., Chen, R., & Zhang, P. (2022) · Mediators of Inflammation · doi:10.1155/2022/7137900 · Cited by 40
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Elkrief, A., Wu, J. T.-Y., Jani, C., Enriquez, K. T., Glover, M. J., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A. C., French, B. C., Jhawar, S. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1368 · Cited by 36
A systematic review on treatment‐related mucocutaneous reactions in COVID ‐19 patients
Nobari, N. N., Seirafianpour, F., Mashayekhi, F., & Goodarzi, A. (2020) · Dermatologic Therapy · doi:10.1111/dth.14662 · Cited by 36
JAK inhibition as a new treatment strategy for patients with COVID-19
Huang, J., Zhou, C., Jinniu, D., & Zhou, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115162 · Cited by 36
Self-citationUV222 disinfection of SARS-CoV-2 in solution
Robinson, R., Mahfooz, N., Mejia, O. R., Liu, Y., & Hull, N. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18385-4 · Cited by 38
Wijaya, I., Andhika, R., Huang, I., Purwiga, A., Budiman, K. Y., Bashari, M. H., Reniarti, L., & Roesli, R. M. A. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2021.100755 · Cited by 37
Cavalli, G., Farina, N., Campochiaro, C., Luca, G. D. D., Della‐Torre, E., Tomelleri, A., & Dagna, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.598308 · Cited by 35
Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2
Jena, N. R. (2021) · Chemical Physics Impact · doi:10.1016/j.chphi.2021.100011 · Cited by 34
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
Jain, N. K., Tailang, M., Jain, H. K., Chandrasekaran, B., Sahoo, B. M., Subramanian, A., Thangavel, N., Aldahish, A. A., Chidambaram, K., Muthumanickam, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1135145 · Cited by 34
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?
Fialho, M. F. P., Brum, E. S., & Oliveira, S. M. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01160-w · Cited by 33
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34
Remdesivir—Bringing Hope for COVID-19 Treatment
Al‐Tannak, N. F., Novotný, L., & Al‐Hunayan, A. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88020029 · Cited by 32
Zhang, X., Shang, L.-H., Fan, G., Gu, X.-Y., Xu, J.-Y., Wang, Y.-M., Huang, L.-X., & Cao, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.800492 · Cited by 28
Self-citationChen, C.-Y., Chen, W., Hsu, C., Chao, C., & Lai, C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108027 · Cited by 31
Zi, F., Ye, L.-L., Zheng, J. F., Cheng, J., & Wang, Q. M. (2021) · Medicine · doi:10.1097/md.0000000000025786 · Cited by 34
Ruxolitinib attenuates secondary injury after traumatic spinal cord injury
Li, H., Yang, L., Cao, X., Qian, Z.-Y., Kong, R.-Y., Zhang, S., Wang, B.-Y., Chang, J., Cao, J., Wu, C.-Q., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335165 · Cited by 33
Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
Tanner, T., & Wahezi, D. M. (2020) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.07.003 · Cited by 30
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
D’Alessio, A., Poggio, P. D., Bracchi, F., Cesana, G., Sertori, N., Mauro, D. D., Fargnoli, A., Motta, M., Giussani, C., Moro, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01087-z · Cited by 30
Patoulias, D., Doumas, M. N., Papadopoulos, C. E., & Karagiannis, A. I. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05884-4 · Cited by 32
Hasselbalch, H. C., Skov, V., Kjær, L., Ellervik, C., Poulsen, A., Poulsen, T. D., & Nielsen, C. H. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.03.006 · Cited by 30
Han, Y. J., Lee, K. H., Yoon, S., Nam, S. W., Ryu, S., Seong, D., Kim, J., Lee, J. Y., Yang, J. W., Lee, J., et al. (2020) · Theranostics · doi:10.7150/thno.48342 · Cited by 28
Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape
Hossain, M. S., Hami, I., Sawrav, M. S. S., Rabbi, M. F., Saha, O., Bahadur, N. M., & Rahaman, M. M. (2020) · Discoveries · doi:10.15190/d.2020.18 · Cited by 27
He, Z., Ye, F., Zhang, C., Fan, J., Du, Z., Zhao, W., Yuan, Q., Niu, W., Gao, F., He, B., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101468 · Cited by 28
Self-citationAlim, K., Bruyère, A., Lescoat, A., Jouan, E., Lecureur, V., Vée, M. L., & Fardel, O. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1862084 · Cited by 26
Repurposing of gastric cancer drugs against COVID-19
Sonkar, C., Doharey, P. K., Rathore, A. S., Singh, V. K., Kashyap, D., Sahoo, A. K., Mittal, N., Sharma, B., & Jha, H. C. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104826 · Cited by 27
Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review
Smail, S. W., Saeed, M., Alkasalias, T., Khudhur, Z. O., Younus, D. A., Rajab, M. F., Abdulahad, W. H., Hussain, H. I., Niaz, K., & Safdar, M. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112087 · Cited by 26
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Su, S.-C., Yang, T., Yu, P., Liang, K.-H., Wy, C., Yang, C.-W., Lin, H.-T., Wang, M.-J. S., Lu, R., Tso, H.-C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009704 · Cited by 24
Murugan, C., Ramamoorthy, S., Kuppuswamy, G. P., Murugan, R. K., Sivalingam, Y., & Sundaramurthy, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.144 · Cited by 28
Ngamprasertchai, T., Kajeekul, R., Sivakorn, C., Ruenroengbun, N., Luvira, V., Siripoon, T., & Luangasanatip, N. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00545-0 · Cited by 25
Khaledi, M., Sameni, F., Yahyazade, S., Radandish, M., Owlia, P., Bagheri, N., Afkhami, H., Mahjoor, M., Esmaelpour, Z., Kohansal, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961027 · Cited by 25
Hyper‐inflammation and complement in COVID ‐19
Pires, B. G., & Calado, R. T. (2023) · American Journal of Hematology · doi:10.1002/ajh.26746 · Cited by 27
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
Khani, E., Khiali, S., & Entezari‐Maleki, T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1822 · Cited by 27
Roles of existing drug and drug targets for COVID-19 management
Ayele, A. G., Enyew, E. F., & Kifle, Z. D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100103 · Cited by 24
He, X., Liu, G., Gong, J., Zhang, Y., Gu, S., Wan, Z., Yang, P., Nie, Y., Wang, Y., Huang, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202203388 · Cited by 24
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12111758 · Cited by 25
Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
Alhajeri, H., Baron, F., Abutiban, F., Mutairi, M. A., Ali, Y., Al-Awadhi, A. M., Albasri, A., Aldei, A., Alenizi, A., Alhadhood, N., et al. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2033563 · Cited by 25
Hernández, P. G., Blanco-Lobo, P., Villaoslada, I., de Felipe, B., Lucena, J. M., Martín-Gutiérrez, G., Castro, M. J., Gutiérrez‐Valencia, A., Sánchez-Códez, M. I., Gaboli, M. P., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01081-9 · Cited by 23
Neubauer, A., Johow, J., Mack, E., Burchert, A., Meyn, D., Kadlubiec, A., Torje, I., Wulf, H., Vogelmeier, C. F., Hoyer, J. D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01374-3 · Cited by 23
Cheng, Q., Chen, J., Jia, Q., Fang, Z., & Zhao, G. (2021) · Aging · doi:10.18632/aging.203522 · Cited by 23
Chu, X., Bu, Y., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785855 · Cited by 24
Morgulchik, N., Athanasopoulou, F., Chu, E., Lam, Y., & Kamaly, N. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0006 · Cited by 23
Zhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 23
Is there any potential management against COVID-19? A systematic review and meta-analysis
Talaie, H., Hosseini, S. M., Nazari, M., Fakhri, Y., Mousavizadeh, A., Vatanpour, H., & Firoozfar, A. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00367-4 · Cited by 22
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
Chatterjee, B., & Thakur, S. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830990 · Cited by 23
Investigational pharmacological agents for the treatment of ARDS
Aribindi, K., Lim, M., Lakshminrusimha, S., & Albertson, T. E. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2315128 · Cited by 22
Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19
Jarai, B. M., Stillman, Z. S., Bomb, K., Kloxin, A. M., & Fromen, C. A. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01287 · Cited by 22
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
Florescu, D. F., & Kalil, A. C. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000869 · Cited by 21
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
Marcuzzi, A., Rimondi, E., Melloni, E., Gonelli, A., Grasso, A. G., Barbi, E., & Maximova, N. (2022) · Pharmaceuticals · doi:10.3390/ph15030374 · Cited by 21
JAK Inhibitors — More Than Just Glucocorticoids
Stebbing, J., & Lauschke, V. M. (2021) · New England Journal of Medicine · doi:10.1056/nejme2108667 · Cited by 21
Rasheed, A., Νοοr, Μ., Usman, Τ., Bilqees, R., Afnan, M., Gul, S., Khan, N. U., Khattak, S., Khattak, I., & Shah, A. A. (2022) · INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR) · doi:10.29052/ijehsr.v10.i2.2022.255-272 · Cited by 20
Isufi, D., Jensen, M. B., Loft, N., Skov, L., Elberling, J., & Alinaghi, F. (2024) · JAAD International · doi:10.1016/j.jdin.2024.09.012 · Cited by 23
Koschmieder, S., Jost, E., Cornelissen, C. G., Müller, T., Schulze-Hagen, M. F., Bickenbach, J., Marx, G., Kleines, M., Marx, N., Brümmendorf, T. H., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13480 · Cited by 20
Sunkara, H., & Dewan, S. M. R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108049 · Cited by 20
Zielińska, A., Eder, P., Karczewski, J., Szalata, M., Hryhorowicz, S., Wielgus, K., Szalata, M., Dobrowolska, A., Atanasov, A. G., Słomski, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147991 · Cited by 22
Novel Antiviral Strategies in the Treatment of COVID-19: A Review
Chen, S., Wang, S.-C., & Chen, Y. (2020) · Microorganisms · doi:10.3390/microorganisms8091259 · Cited by 20
López‐Medrano, F., Asín, M. A. P., Fernández‐Ruiz, M., Carretero, O., Lalueza, A., de la Calle, G. M., Manuel, J., de la Calle, C., Catalán, M., García-García, R., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.099 · Cited by 19
VIu, M., Orlova, Y. A., Павликова, Е. П., Akopyan, Z. A., Мацкеплишвили, С. Т., Геннадьевна, П. А., Seredenina, E. M., Potapenko, A. V., Малахов, П. С., Samokhodskaya, L. M., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.9.n1338 · Cited by 20
Li, D., Hu, J., Li, D., Yang, W., Yin, S., & Qiu, R. (2021) · Topics in Current Chemistry · doi:10.1007/s41061-020-00318-2 · Cited by 18
Anand, K., Vadivalagan, C., Joseph, J. S., Singh, S. K., Gulati, M., Shahbaaz, M., Abdellattif, M. H., Prasher, P., Gupta, G., Chellappan, D. K., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109497 · Cited by 19
Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches
Choi, H., & Shin, E. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.1.152 · Cited by 19
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Xue, Y., Mei, H., Chen, Y., Griffin, J. D., Liu, Q., Weisberg, E., & Yang, J. C. (2023) · MedComm · doi:10.1002/mco2.254 · Cited by 20
Zhang, T., Tian, W., Wei, S., Lu, X., An, J., He, S., Zhao, J., Gao, Z., Li, L., Lian, K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00426-x · Cited by 19
Self-citationRojas, P., & Mauricio Sarmiento, M. (2020) · Acta Haematologica · doi:10.1159/000510179 · Cited by 19
COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?
Gallo, C. G., Fiorino, S., Posabella, G., Antonacci, D., Tropeano, A., Pausini, E., Pausini, C., Guarniero, T., Hong, W., Giampieri, E., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155628 · Cited by 17
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z., Baghbanzadeh, A., Nakhlband, A., Baradaran, B., Jafari, S., Bagheri, Y., Raei, F., Montazersaheb, S., & Farahzadi, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120809 · Cited by 20
JAK-STAT signaling as an ARDS therapeutic target: Status and future trends
Zhang, Y., Gao, Z., Jiang, F., Yan, H., Yang, B., He, Q., Luo, P., Xu, Z., & Yang, X. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115382 · Cited by 18
Asano, T., Noma, K., Mizoguchi, Y., Karakawa, S., & Okada, S. (2023) · Immunological Reviews · doi:10.1111/imr.13300 · Cited by 23
Jyonouchi, H. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1333717 · Cited by 20
Barbarino, V., Henschke, S., Blakemore, S. J., Izquierdo, E., Michalik, M., Nickel, N., Möllenkotte, I., Vorholt, D., Müller, L., Brinker, R., et al. (2020) · Cancers · doi:10.3390/cancers12082303 · Cited by 18
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience
Xue, E., Lorentino, F., Pavesi, F., Assanelli, A. A., Peccatori, J., Bernardi, M., Corti, C., Ciceri, F., & Stanghellini, M. T. L. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106642 · Cited by 19
Kumar, A., Sharma, A., Tirpude, N. V., Sharma, S., Padwad, Y. S., & Kumar, S. (2022) · Inflammopharmacology · doi:10.1007/s10787-021-00903-x · Cited by 18
Liu, J. M., & Chi, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702211068840 · Cited by 18
Self-citationImmunomodulatory therapies for COVID-19
Mathur, P., & Kottilil, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.921452 · Cited by 17
Wei, L., Yang, L., Cong, J., Ye, J., Li, X., Yao, N., Yang, H. J., Ding, J., & Wang, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03376-7 · Cited by 17
Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review
Starshinova, A. A., Malkova, A. M., Zinchenko, Y. S., Kudlay, D. A., Glushkova, A. V., Dovgalyk, I., Yаblonskiy, P. K., & Shoenfeld, Y. (2021) · Life · doi:10.3390/life11080753 · Cited by 18
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
Conway, S. R., Keller, M. D., & Bollard, C. M. (2022) · Blood · doi:10.1182/blood.2021012249 · Cited by 17
Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review
Wang, C., Xiao, X., Feng, H., Hong, Z., Li, M., Tu, N., Li, X., Wang, K., & Bu, L. (2021) · Current Microbiology · doi:10.1007/s00284-021-02413-z · Cited by 16
Kow, C. S., Hasan, S. S., & Ramachandram, D. S. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01200-5 · Cited by 16
Metadata
- Authors
- Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., & Zhou, J.
- Affiliations
- Tongji Hospital (CN)
- Wuhan No.1 Hospital (CN)
- Third Xiangya Hospital (CN)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Huang, Gang
- Wang, Wei
- Zhou, Jianfeng
- ORCID
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 146
- Issue
- 1
- Pages
- 137-146.e3
- ISSN
- 0091-6749 (ISSN-L)
- PMC
- PMC7250105
- OpenAlex
- W3030158388
- Cited by
- 456
- References
- 38
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 24 · 2023: 45 · 2022: 95 · 2021: 178 · 2020: 103
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Emergency Research Project of Tongji Hospital
- Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology (2020kfyXGYJ045)
- Emergency Research Project of Hubei province (2020FCA006)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- ruxolitinib, COVID-19 pandemic, severe COVID-19, JAK1/2 inhibitor, JAK inhibitors, cytokine levels, mortality, drug safety, antiviral therapy
- MeSH terms
- Betacoronavirus, Janus Kinase Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Female, Humans, Male, Middle Aged, Nitriles, Pneumonia, Viral, Pyrazoles, Pyrimidines, Single-Blind Method, Treatment Outcome, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
